<DOC>
	<DOCNO>NCT00135382</DOCNO>
	<brief_summary>The purpose study demonstrate virologically control HIV-infected individual successfully switch protease inhibitor ( PI ) -based regimen efavirenz-based regimen maintain virologic control , evaluate proportion subject continue plasma HIV-1 level &lt; 50 copies/mL . In addition , simplify once-daily regimen improve adherence quality life .</brief_summary>
	<brief_title>Study Switching HIV-1 Infected Patients With Undetectable Viral Load First Protease Inhibitor-Based Regimen Efavirenz-Based Regimen</brief_title>
	<detailed_description>Patients randomize non Videx enteric coat ( ddl EC ) +lamivudine ( 3TC ) +efavirenz ( EFV ) arm would continue baseline nucleoside reverse transcriptase inhibitor ( NRTIs ) study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Documented HIV infection ≥ 18 year age weight least 40kg Two plasma HIV RNA level &lt; 50 copies/mL qualification screen period Patients receive PI ≥ 2 NRTIs Pregnancy breastfeed Documented virologic failure first PIbased antiretroviral ( ARV ) regimen Active AIDSdefining opportunistic infection disease Proven suspect acute hepatitis within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>HIV/AIDS</keyword>
</DOC>